ProfileGDS5678 / 1447706_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 74% 71% 68% 73% 73% 73% 73% 70% 73% 71% 71% 72% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.557472
GSM967853U87-EV human glioblastoma xenograft - Control 24.8879874
GSM967854U87-EV human glioblastoma xenograft - Control 34.4509471
GSM967855U87-EV human glioblastoma xenograft - Control 44.1692268
GSM967856U87-EV human glioblastoma xenograft - Control 54.7006173
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6690973
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6848873
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7368373
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3220270
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7490173
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4060871
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4664371
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5736772
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6947673